Tianjin Kilo Pharmaceutical Added to Import Alert 66-40: The CGMP…

Regulatory Event

On July 21, 2026, the Food and Drug Administration (FDA) added Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd. to Import Alert 66-40, the agency’s Detention Without Physical Examination (DWPE) list for firms that have not met drug current Good Manufacturing Practice (CGMP) requirements. The listing covers the firm’s facility in Huayuan High-tech Industrial Park, Tianjin, China, and it is a comprehensive, facility-wide action rather than a single-line detention: the Red List entry spans ten distinct FDA product codes, including vitamins/minerals and dietary-supplement-as-drug lines across prescription, non-prescription, and investigational categories, pharmaceutical necessities and containers, antibiotics, Human and Animal Therapeutic Biologic and Biosimilar Drugs, and general human and animal drug categories. Every product line covered by the listing is now subject to automatic detention at the US port of entry; release requires the importer to demonstrate CGMP conformance to the Center for Drug Evaluation and Research (CDER) before any shipment clears. Public trade and supplier directory sources describe Tianjin Kilo as a specialty and fine-chemical manufacturer focused on organic synthesis, Active Pharmaceutical Ingredients (APIs), advanced intermediates, and fluorochemicals — a mid-size specialty API supplier profile rather than a large, globally branded finished-dose manufacturer. That company background comes from independent trade sources, not from the FDA listing itself, and has not been verified against whatever CGMP finding actually triggered this action.

What FDA has not published alongside the listing is a specific deficiency narrative. IA 66-40 entries do not always carry one, and this is such a case: the Red List cites the standard “not operating in conformity with CGMP requirements” language uniformly across all ten product-code rows, without breaking out a distinct finding for any single line. No Form 483, no inspection classification, and no companion Warning Letter for Tianjin Kilo Pharmaceutical was located in FDA’s public Warning Letter database or in general web search as of this writing. (A similarly named but unrelated firm, Tianjin Darentang Jingwanhong Pharmaceutical Co., Ltd., received an FDA Warning Letter in October 2024 for inspection-refusal conduct — a different legal entity, noted only to avoid confusion, not a companion document for this listing.) What stands out here is the mismatch between the apparent scale of the company and the breadth of the DWPE scope: a specialty fine-chemical and API supplier being listed across biologics/biosimilar, antibiotic, and general drug product codes suggests FDA scoped the detention to everything the facility is registered to manufacture, consistent with a facility-wide quality system finding rather than a contamination or potency event isolated to one product line.

What the Record Documents

DWPE is not a warning; it is an operational barrier. Under Section 801 of the Federal Food, Drug, and Cosmetic Act and 21 CFR § 1.94, FDA may detain a shipment without physical examination once the exporting firm appears on the IA 66-40 Red List, and the burden falls to the owner, consignee, or other responsible party to provide documentation showing the CGMP violation has been adequately corrected before release will be considered. In practice, every US customer sourcing APIs, intermediates, or finished drug products from this facility now faces halted supply unless the importer of record initiates a Compliance Monitoring Program (CMP): a validated sampling plan, testing through an FDA-qualified laboratory, and batch-by-batch release submissions to the responsible FDA district office, sustained until FDA is willing to schedule a reinspection.

Prior IA 66-40 cases involving facility-wide, multi-category listings offer a useful reference point for scale and timeline, even where the deficiency category differs. Wockhardt’s Waluj facility was listed in 2013 following an FDA inspection documenting data manipulation under 21 CFR §§ 211.68(b) and 211.194(a); the resulting CMP covered the site’s entire finished product line, and Wockhardt’s US revenue declined an estimated $130 million in the following year as customers qualified alternative suppliers. Ranbaxy’s Paonta Sahib facility, similarly listed for data integrity failures under § 211.194(a), required more than four years of batch-by-batch CMP testing before reinspection. Those cases involved large-volume generic manufacturers; Tianjin Kilo’s apparent scale as a specialty API/fine-chemical supplier is smaller, and the specific deficiency category here has not been publicly confirmed. What the precedents establish as a general mechanism, regardless of company size, is that DWPE does not lift until a firm demonstrates — through sustained CMP performance and a satisfactory reinspection — that the underlying quality system, not just the language on the Red List, has been corrected.

Technical and Quality Context

For Tianjin Kilo, a credible remediation pathway starts with transparency: engaging the FDA district office responsible for the listing, obtaining the underlying inspection findings if a Form 483 or equivalent record exists, and building a Corrective and Preventive Action (CAPA) program scoped to whatever CGMP gap FDA actually identified, rather than to the general language on the Red List. Given the blanket nature of the listing across ten product codes, a credible corrective action plan will likely need to address quality system fundamentals across the full manufacturing operation rather than a single product line — component testing and specification controls under 21 CFR § 211.84, production and process control review before batch release under § 211.192, and laboratory record integrity under § 211.194(a) are among the areas that general CGMP non-conformance findings most commonly touch for multi-category API and fine-chemical manufacturers, based on the pattern reflected in prior IA 66-40 actions, though the specific deficiency here has not been publicly confirmed.

US companies that source APIs, intermediates, or finished drug products from Tianjin Kilo should treat this listing as a supplier qualification trigger regardless of the deficiency detail gap. That means auditing current inventory and supply agreements against this facility, confirming with any distributor or repackager whether Tianjin Kilo material sits further upstream in a supply chain, and beginning an alternative-sourcing assessment in parallel with monitoring FDA’s Warning Letter postings for the underlying finding. Companies that wait for a companion Warning Letter to appear before acting are, in effect, letting detained shipments define their sourcing risk rather than getting ahead of it.

Decision Relevance

XGene Consulting supports companies at both ends of this exposure: importers and brand owners assessing whether a listed supplier’s CGMP gaps create downstream liability, and manufacturers like Tianjin Kilo building the CMP documentation package, root cause assessment, and reinspection readiness plan FDA expects before considering removal from Import Alert 66-40. If you manage a supplier relationship tied to a site on Import Alert 66-40, or you are the site working to get off it, connect with me on LinkedIn or through xgeneconsulting.com — the earlier a disciplined CMP strategy starts, the shorter the DWPE period tends to run.